{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:32:29Z","timestamp":1780504349126,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Der Stellenwert der Opioide bei nichttumorbedingten Schmerzen wird kontrovers diskutiert. Aus Deutschland fehlen aktuelle Daten zur Opioidverordnung bei nichttumorbedingtem Schmerz.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Daten zur Pr\u00e4valenz von kurz- und langfristigen Opioidverordnungen, verschriebenen Wirkstoffen, Komedikation, verschreibenden Fachgruppen und demografischen und klinischen Charakteristika der Patienten.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Retrospektive Analyse von Abrechnungsdaten erwachsener BARMER-Versicherter ohne Hinweis auf einen b\u00f6sartigen Tumor f\u00fcr das Jahr 2021 (<jats:italic>n<\/jats:italic>\u202f=\u20096.771.075) sowie Versicherter mit Neubeginn einer Opioidtherapie in 2019 (<jats:italic>n<\/jats:italic>\u202f=\u2009142.598).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>5,7\u202f% der Versicherten ohne Krebsdiagnose erhielten in 2021 mindestens eine Opioidverordnung, 1,9\u202f% eine Langzeittherapie. Tilidin und Tramadol waren die am h\u00e4ufigsten verordneten Opioide in Kurz- und Langzeittherapie. Frauen erhielten h\u00e4ufiger Opioide als M\u00e4nner. Die Verordnungsh\u00e4ufigkeit stieg mit dem Alter deutlich an. In 2021 erhielten 22,5\u202f% der Versicherten mit Langzeitopioidtherapie eine Komedikation mit Pregabalin und\/oder Gabapentin, 37,5\u202f% mit einem Antidepressivum und 58,1\u202f% mit Metamizol und\/oder nichtsteroidale Antirheumatika (NSAR). Erstverordnungen erfolgten zu 59,5\u202f% durch Haus\u00e4rzte. Im ersten Therapiejahr waren bei Personen mit Langzeitopioidtherapie im Mittel\u00a02,1\u00a0Praxen an der Schmerzmittelverordnung beteiligt, 13\u00a0verschiedene chronische Krankheiten wurden dokumentiert.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diskussion<\/jats:title>\n            <jats:p>Die Opioidtherapie nichttumorbedingter Schmerzen findet \u00fcberwiegend im haus\u00e4rztlichen Bereich bei \u00e4lteren, multimorbiden Patienten statt. Die Indikationsstellung erfordert eine gemeinsame Entscheidungsfindung mit Patientinnen und Patienten und gegebenenfalls ihren Angeh\u00f6rigen sowie die \u00dcberpr\u00fcfung m\u00f6glicher Arzneimittelinteraktionen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphic abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00482-024-00852-8","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:04:09Z","timestamp":1733393049000},"page":"359-368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Opioidverordnungen bei Versicherten\u00a0ohne\u00a0Krebserkrankung in Deutschland\u00a0\u2013 Daten\u00a0der\u00a0BARMER","Opioid prescriptions for insured individuals without cancer in Germany: data from the BARMER"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0526-5350","authenticated-orcid":false,"given":"Veronika","family":"Lappe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Petzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"852_CR1","volume-title":"Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben f\u00fcr Deutschland im Jahre 2023","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte \u2013 BfArM","year":"2023","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte \u2013 BfArM (2023) Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben f\u00fcr Deutschland im Jahre 2023"},{"key":"852_CR2","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) ICD-10-GM Version 2022 Systematisches Verzeichnis. https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Services\/Downloads\/_node.html. Zugegriffen: 22. Jan. 2024"},{"key":"852_CR3","unstructured":"Centers for Disease Control and Prevention (2018) Annual surveillance report of drug-related risks and outcomes\u2014United States. Surveillance special report 2. https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2018-cdc-drug-surveillance-report.pdf. Zugegriffen: 6. Jan. 2024"},{"key":"852_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7326\/M14-2559","volume":"162","author":"R Chou","year":"2015","unstructured":"Chou\u00a0R, Turner\u00a0JA, Devine\u00a0EB et\u00a0al (2015) The effectiveness and risks of long-term opioid therapy for chronic pain: a\u00a0systematic review for a\u00a0national institutes of health pathways to prevention workshop. Ann Intern Med 162:276\u2013286","journal-title":"Ann Intern Med"},{"key":"852_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone\u00a0D (2021) The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry 34:344\u2013350","journal-title":"Curr Opin Psychiatry"},{"key":"852_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s00482-020-00456-y","volume":"34","author":"P Cremer-Schaeffer","year":"2020","unstructured":"Cremer-Schaeffer\u00a0P, Sommer\u00a0C (2020) Langzeitanwendung von Opioiden bei chronischen nicht tumorbedingten Schmerzen (LONTS\u00a03). Schmerz 34:200\u2013203","journal-title":"Schmerz"},{"key":"852_CR7","volume-title":"Behandlung akuter perioperativer und Posttraumatischer Schmerzen","author":"Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin E.V (DGAI)","year":"2021","unstructured":"Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin E.V (DGAI) (2021) Behandlung akuter perioperativer und posttraumatischer Schmerzen (AWMF-Register Nr.001\/025. Klasse: S3)"},{"key":"852_CR8","unstructured":"Deutscher Bundestag (2020) Keine Opioid-Krise wie in den USA. https:\/\/www.bundestag.de\/webarchiv\/presse\/hib\/2020_01\/675924-675924. Zugegriffen: 6. Jan. 2024"},{"key":"852_CR9","unstructured":"Deutscher Bundestag (2019) Keine Opioid-Krise wie in den USA. https:\/\/www.bundestag.de\/webarchiv\/presse\/hib\/2019_04\/635928-635928. Zugegriffen: 6. Jan. 2024"},{"key":"852_CR10","unstructured":"Grandt D, Gamst\u00e4tter T (2023) S2k-Leitlinie Arzneimitteltherapie bei Multimorbidit\u00e4t\u2014Living Guideline. https:\/\/register.awmf.org\/assets\/guidelines\/100-001l_S2k_Arzneimitteltherapie-bei-Multimorbiditaet_2023-04.pdf. Zugegriffen: 6. Jan. 2024 (AWMF Register-Nr. 100-001)"},{"key":"852_CR11","volume-title":"Arzneimittelreport 2023: Medikament\u00f6se Schmerztherapie nicht-onkologischer ambulanter Patientinnen und Patienten","author":"D Grandt","year":"2023","unstructured":"Grandt\u00a0D, Lappe\u00a0V, Schubert\u00a0I (2023) Arzneimittelreport 2023: Medikament\u00f6se Schmerztherapie nicht-onkologischer ambulanter Patientinnen und Patienten. BARMER, Berlin"},{"issue":"1","key":"852_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00482-012-1280-z","volume":"27","author":"W H\u00e4user","year":"2013","unstructured":"H\u00e4user\u00a0W, Schmutzer\u00a0G, Hinz\u00a0A et\u00a0al (2013) Pr\u00e4valenz chronischer Schmerzen in Deutschland. Befragung einer repr\u00e4sentativen Bev\u00f6lkerungsstichprobe. Schmerz 27(1):46\u201355","journal-title":"Schmerz"},{"issue":"1","key":"852_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00482-014-1463-x","volume":"29","author":"W H\u00e4user","year":"2015","unstructured":"H\u00e4user\u00a0W, Bock\u00a0F, Engeser\u00a0P et\u00a0al (2015) Empfehlungen der aktualisierten Leitlinie LONTS. Langzeitanwendung von Opioiden bei chronischen nicht-tumorbedingten Schmerzen. Schmerz 29(1):109\u2013130","journal-title":"Schmerz"},{"key":"852_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00482-020-00472-y","volume":"34","author":"W H\u00e4user","year":"2020","unstructured":"H\u00e4user\u00a0W, Bock\u00a0F, H\u00fcppe\u00a0M et\u00a0al (2020) Empfehlungen der zweiten Aktualisierung der Leitlinie LONTS. Schmerz 34:204\u2013244","journal-title":"Schmerz"},{"key":"852_CR15","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/ejp.1786","volume":"25","author":"W H\u00e4user","year":"2021","unstructured":"H\u00e4user\u00a0W, Buchser\u00a0E, Finn\u00a0DP et\u00a0al (2021) Is Europe also facing an opioid crisis? A\u00a0survey of European Pain Federation Chapters. Eur J Pain 25:1760\u20131769","journal-title":"Eur J Pain"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00482-014-1438-y","volume":"28","author":"W H\u00e4user","year":"2014","unstructured":"H\u00e4user\u00a0W, Schmutzer\u00a0G, Henningsen\u00a0P et\u00a0al (2014) Chronische Schmerzen, Schmerzkrankheit und Zufriedenheit der Betroffenen mit der Schmerzbehandlung in Deutschland. Schmerz 28:483\u2013492","journal-title":"Schmerz"},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00482-018-0324-4","volume":"32","author":"W H\u00e4user","year":"2018","unstructured":"H\u00e4user\u00a0W, Schubert\u00a0T, Scherbaum\u00a0N et\u00a0al (2018) Langzeitopioidtherapie von nichttumorbedingten Schmerzen. Schmerz 32:419\u2013426","journal-title":"Schmerz"},{"key":"852_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0031-1275711","volume":"74","author":"F Hoffmann","year":"2012","unstructured":"Hoffmann\u00a0F, Icks\u00a0A (2012) Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen f\u00fcr die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen 74:291\u2013297","journal-title":"Gesundheitswesen"},{"key":"852_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(23)00404-X","volume":"402","author":"CMP Jones","year":"2023","unstructured":"Jones\u00a0CMP, Day\u00a0RO, Koes\u00a0BW et\u00a0al (2023) Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a\u00a0randomised placebo-controlled trial. Lancet 402:304\u2013312","journal-title":"Lancet"},{"key":"852_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/ejp.1744","volume":"25","author":"N Kr\u010devski \u0160kvar\u010d","year":"2021","unstructured":"Kr\u010devski \u0160kvar\u010d\u00a0N, Morlion\u00a0B, Vowles\u00a0KE et\u00a0al (2021) European clinical practice recommendations on opioids for chronic noncancer pain\u2014part\u00a02: special situations. Eur J Pain 25:969\u2013985","journal-title":"Eur J Pain"},{"key":"852_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ejp.802","volume":"20","author":"U Marschall","year":"2016","unstructured":"Marschall\u00a0U, L\u2019hoest\u00a0H, Radbruch\u00a0L et\u00a0al (2016) Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain 20:767\u2013776","journal-title":"Eur J Pain"},{"key":"852_CR22","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/j.pain.0000000000003239","volume":"165","author":"S Muller","year":"2024","unstructured":"Muller\u00a0S, Bailey\u00a0J, Bajpai\u00a0R et\u00a0al (2024) Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a\u00a0cohort study. Pain 165:2282\u20132290","journal-title":"Pain"},{"key":"852_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jama.2015.12397","volume":"314","author":"LS Nelson","year":"2015","unstructured":"Nelson\u00a0LS, Juurlink\u00a0DN, Perrone\u00a0J (2015) Addressing the opioid epidemic. JAMA 314:1453\u20131454","journal-title":"JAMA"},{"key":"852_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ajem.2022.05.022","volume":"58","author":"MA Rech","year":"2022","unstructured":"Rech\u00a0MA, Griggs\u00a0C, Lovett\u00a0S et\u00a0al (2022) Acute pain management in the emergency department: use of multimodal and non-opioid analgesic treatment strategies. Am J Emerg Med 58:57\u201365","journal-title":"Am J Emerg Med"},{"issue":"5","key":"852_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00482-009-0839-9","volume":"23","author":"H Reinecke","year":"2009","unstructured":"Reinecke\u00a0H, Sorgatz\u00a0H (2009) German Society for the Study of Pain (DGSS) (2009) S3-Leitlinie LONTS. Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen. Schmerz 23(5):440\u2013447","journal-title":"Schmerz"},{"key":"852_CR26","doi-asserted-by":"publisher","first-page":"e0221153","DOI":"10.1371\/journal.pone.0221153","volume":"14","author":"B Rosner","year":"2019","unstructured":"Rosner\u00a0B, Neicun\u00a0J, Yang\u00a0JC et\u00a0al (2019) Opioid prescription patterns in Germany and the global opioid epidemic: systematic review of available evidence. PLoS ONE 14:e221153","journal-title":"PLoS ONE"},{"key":"852_CR27","volume-title":"Multimorbidit\u00e4t S3-Leitlinie: AMWF-Register-Nr. 053-047, DEGAM-Leitlinie Nr.\u00a020","author":"M Scherer","year":"2017","unstructured":"Scherer\u00a0M, Wagner\u00a0H\u2011O, L\u00fchmann\u00a0D et\u00a0al (2017) Multimorbidit\u00e4t S3-Leitlinie: AMWF-Register-Nr. 053-047, DEGAM-Leitlinie Nr.\u00a020. Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin e.\u202fV., Berlin"},{"key":"852_CR28","first-page":"45","volume":"110","author":"I Schubert","year":"2013","unstructured":"Schubert\u00a0I, Ihle\u00a0P, Sabatowski\u00a0R (2013) Increase in opiate prescription in Germany between 2000 and 2010: a\u00a0study based on insurance data. Dtsch \u00c4rztebl Int 110:45\u201351","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"852_CR29","unstructured":"US Food and Drug Administration (2019) FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression. Zugegriffen: 6. Jan. 2024"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-024-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-024-00852-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-024-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:17:00Z","timestamp":1758197820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-024-00852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s00482-024-00852-8","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"18 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.\u00a0Lappe und I.\u00a0Schubert erhielten f\u00fcr die PMV forschungsgruppe (Uniklinik K\u00f6ln) Drittmittel durch die BARMER, D.\u00a0Grandt erhielt Honorare von der BARMER, U.\u00a0Marschall ist Angestellte der BARMER, F.\u00a0Petzke und W.\u00a0H\u00e4user haben keine materiellen Interessenkonflikte, sie sind Mitautoren der LONTS-Leitlinie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}